The role of drug-eluting balloon catheters in the treatment of coronary in-stent restenosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F18%3AE0107685" target="_blank" >RIV/00843989:_____/18:E0107685 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The role of drug-eluting balloon catheters in the treatment of coronary in-stent restenosis

Popis výsledku v původním jazyce

Coronary stent implantation has significantly improved percutaneous coronary interventions and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20-35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5-10%. Evidence from controlled clinical studies has suggested that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR. In contrast to the DES, the DEB allows short-term passage of the active substance into the vascular wall, preventing hyperproliferation of vascular smooth muscle cells, however, due to the short duration of the effect, DEB do not affect endothelial progenitor cells and stent neoendothelialization so much. Here, we discuss some recent randomized studies that compared different DEB with DES use to treat BMS-ISR or DES-ISR, and the long-term clinical results of those studies.

Název v anglickém jazyce

The role of drug-eluting balloon catheters in the treatment of coronary in-stent restenosis

Popis výsledku anglicky

Coronary stent implantation has significantly improved percutaneous coronary interventions and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20-35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5-10%. Evidence from controlled clinical studies has suggested that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR. In contrast to the DES, the DEB allows short-term passage of the active substance into the vascular wall, preventing hyperproliferation of vascular smooth muscle cells, however, due to the short duration of the effect, DEB do not affect endothelial progenitor cells and stent neoendothelialization so much. Here, we discuss some recent randomized studies that compared different DEB with DES use to treat BMS-ISR or DES-ISR, and the long-term clinical results of those studies.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Horizons in World Cardiovascular Research

ISBN

978-1-53614-184-9

Počet stran výsledku

24

Strana od-do

133-156

Počet stran knihy

250

Název nakladatele

Nova Science Publishers,

Místo vydání

New York, USA : Nova Science Publishers, 2018

Kód UT WoS kapitoly

—